Mergers & Acquisitions Activity in the Biotech Industry at a Four-Year High
August 22 2012 - 7:20AM
Marketwired
Biotechnology stocks continue to be some of the strongest
performers in the markets as favorable legislation, such as the
FAST and TREAT acts, have helped boost investor optimism within the
industry. The iShares Nasdaq Biotechnology Index Fund is up over 28
percent in 2012 -- handedly outperforming the Dow Jones industrial
average year-to-date. Five Star Equities examines the outlook for
companies in the Biotech Industry and provides equity research on
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) and ImmunoCellular
Therapeutics Ltd. (NYSE: IMUC).
Access to the full company reports can be found at:
www.FiveStarEquities.com/IDIX www.FiveStarEquities.com/IMUC
The FAST and TREAT acts introduced in 2012 have helped
accelerate the development, review and approval process of
medicines/personalized therapies for patients suffering from
serious and life-threatening diseases. According to recent data
from Thomson Reuters, biotech mergers & acquisitions activity
is currently at a four-year high as large pharmaceuticals are
facing major patent cliffs. So far in 2012 the volume of biotech
M&A has exceeded $25 billion, compared to roughly 10 billion in
the same period of 2011.
"Their patents have expired, and as a result they have holes in
their revenue line they are trying to fill," said Scott Lindsay,
global head of mergers and acquisitions at Credit Suisse. "The
other part is just shoring up the pipeline they have. So even if
they don't have a major patent problem, they're all looking for
growth."
Five Star Equities releases regular market updates on the
Biotech Industry so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.FiveStarEquities.com and
get exclusive access to our numerous stock reports and industry
newsletters.
Idenix Pharmaceuticals is a biopharmaceutical company engaged in
the discovery and development of drugs for the treatment of human
viral diseases. Idenix's current focus is on the treatment of
patients with hepatitis C infection. Shares of the company fell
nearly 30 percent last Thursday after reporting that they have
received verbal notice from the FDA that a partial clinical hold
has been placed on IDX184, a clinical development program.
ImmunoCellular Therapeutics is a Los Angeles-based
clinical-stage company that is developing immune-based therapies
for the treatment of brain and other cancers. ImmunoCellular has
commenced a Phase II trial of its lead product candidate, ICT-107,
a dendritic cell-based vaccine targeting multiple tumor-associated
antigens for glioblastoma.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024